Bomhof MR, et al. - In this placebo-controlled, randomized pilot trial, researchers determined if a prebiotic supplement to improve histological parameters of non-alcoholic steatohepatitis (NASH) would demonstrate the therapeutic potential. They randomized individuals with liver-biopsy-confirmed NASH [non-alcoholic fatty liver activity score (NAS) ≥ 5] to receive oligofructose (8 g/day for 12 weeks followed by 16 g/day for 24 weeks) or isocaloric placebo for 9 months. They examined the change in liver biopsy NAS score and changes in body weight, body composition, glucose tolerance, inflammatory markers, and gut microbiota. They found that histologically-confirmed steatosis attenuated following prebiotic supplementation in patients with NASH. This effect was independent of other lifestyle changes.